1. Home
  2. SPRO vs ONEG Comparison

SPRO vs ONEG Comparison

Compare SPRO & ONEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • ONEG
  • Stock Information
  • Founded
  • SPRO 2013
  • ONEG 2021
  • Country
  • SPRO United States
  • ONEG Hong Kong
  • Employees
  • SPRO N/A
  • ONEG N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • ONEG Homebuilding
  • Sector
  • SPRO Health Care
  • ONEG Consumer Discretionary
  • Exchange
  • SPRO Nasdaq
  • ONEG Nasdaq
  • Market Cap
  • SPRO 45.7M
  • ONEG 38.2M
  • IPO Year
  • SPRO 2017
  • ONEG 2024
  • Fundamental
  • Price
  • SPRO $0.72
  • ONEG $2.19
  • Analyst Decision
  • SPRO Buy
  • ONEG
  • Analyst Count
  • SPRO 4
  • ONEG 0
  • Target Price
  • SPRO $5.00
  • ONEG N/A
  • AVG Volume (30 Days)
  • SPRO 118.7K
  • ONEG 28.3K
  • Earning Date
  • SPRO 03-27-2025
  • ONEG 01-01-0001
  • Dividend Yield
  • SPRO N/A
  • ONEG N/A
  • EPS Growth
  • SPRO N/A
  • ONEG N/A
  • EPS
  • SPRO N/A
  • ONEG 0.16
  • Revenue
  • SPRO $47,977,000.00
  • ONEG $63,463,000.00
  • Revenue This Year
  • SPRO N/A
  • ONEG N/A
  • Revenue Next Year
  • SPRO N/A
  • ONEG N/A
  • P/E Ratio
  • SPRO N/A
  • ONEG $20.22
  • Revenue Growth
  • SPRO N/A
  • ONEG 16.46
  • 52 Week Low
  • SPRO $0.70
  • ONEG $1.96
  • 52 Week High
  • SPRO $1.81
  • ONEG $4.05
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 38.19
  • ONEG N/A
  • Support Level
  • SPRO $0.75
  • ONEG N/A
  • Resistance Level
  • SPRO $0.80
  • ONEG N/A
  • Average True Range (ATR)
  • SPRO 0.05
  • ONEG 0.00
  • MACD
  • SPRO 0.00
  • ONEG 0.00
  • Stochastic Oscillator
  • SPRO 9.09
  • ONEG 0.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

Share on Social Networks: